Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org)

Home > Drug Product Listings > > Printer-friendly PDF

Denosumab

Trade Name: Prolia Manufacturer/Distributor: Amgen Canada 1 (800) 665-4273 ; Medical information 1 (866) 502-6436 Classification: RANK Ligand inhibitor ATC Class: M05BX04 Denosumab Status: active Notice of Compliance (yyyy/mm/dd): 2010/08/06 Date Marketed in Canada (yyyy/mm/dd): 2010/08/10 Presentation: Injection: 60 mg/mL pre-filled syringe. DIN: 02343541 Comments: metabolism regulator for prevention of fractures in post-menopausal women with osteoporosis. Product is injected subcutaneously every six months. Keywords: denosumab fractures osteoporosis Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status: ?

Search Terms:

Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Date Marketed in Common Trade Generic Name Classification Canada Name(s) (yyyy/mm/dd) Selective serotonin Escitalopram Cipralex MELTZ 2013/01/15 reuptake inhibitor Esketamine Spravato Antidepressant 2020/05/20 Esomeprazole + Vimovo NSAID + PPI 2011/01/14 Naproxen Hormone replacement Estradiol Vagifem 2011/12/31 therapy Estradiol gel Divigel Topical estrogen 2012/10 Estropipate Ogen Eszopiclone Lunesta Hypnotic 2020/10/20 Ethinyl estradiol + Seasonique Oral contraceptive 2011/04/15 levonorgestrel Ethinyl estradiol + Lolo Oral contraceptive 2014/07/03 norethindrone Ethinyl estradiol + Ovral Oral contraceptive norgestrel Etonogestrel Nexplanon Hormonal contraceptive 2020/08/17 Everolimus Afinitor Antineoplastic agent 2010/02/12 Byetta Incretin mimetic 2011/04/20 Exenatide Bydureon Incretin mimetic 2016/02/16 Fampridine Fampyra Multiple sclerosis agent 2012/04/17 Xanthine oxidase Febuxostat Uloric 2010/09/30 inhibitor Fentanyl Duragesic Opioid anaglesic 2009/05/21 Fentanyl Onsolis Opioid analgesic 2011/08 Fentanyl Abstral Opioid analgesic 2011/06/13 Fesoterodine Toviaz Urinary antispasmodic 2012/05/31 Fidaxomicin Dificid Antibacterial agent 2012/06 Sphingosine 1- Fingolimod Gilenya phosphate receptor 2011/04/04 modulator Flibanserin ADDYI CNS agent 2018/02/27 Date Marketed in Common Trade Generic Name Classification Canada Name(s) (yyyy/mm/dd) Benzodiazepine Flumazenil Anexate 2012/02/28 antagonist Fosfomycin Monurol Urinary anti-infective 2012/09/25 Anti-calcitonin gene- Fremanezumab Ajovy 2020/08/04 related Emgality CGRP binding antibody 2019/10/02 Garamycin eye drops; Garamycin Gentamicin Antibiotic 2012/04/01 ear drops; Garasone eye/ear drops Gilteritinib Xospata Antineoplastic agent 2020/02/03 Glasdegib Daurismo Antineoplastic agent 2020/08/10 Antiviral agent for Glecaprevir + Maviret treatment of chronic 2017/09/13 pibrentasvir hepatitis C infection Sulfonylurea Gliclazide Diamicron MR 2010/12/13 hypoglycemic agent Glucagon Baqsimi Hyperglycemic agent 2019/11/20 Antimuscarinic Glycopyrrolate Cuvposa 2018/04/03 antispasmodic agent Glycopyrronium Seebri Breezhaler Anticholinergic agent 2013/01/29 bromide Tumor necrosis factor Golimumab Simponi alpha inhibitor 2009/07 (DMARD) « first? previous 1 2 3 4 5 6 7 8 9 ? next ? last »

© 2017 BC Drug and Poison Information Centre All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases. Terms and Conditions

Source URL (retrieved on 2021-10-02 13:47): http://www.dpic.org/druglisting/denosumab